Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105627 | 0.82 | PTGS2 (0.43) | KIF11PTGS2SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL23312355 | 0.77 | PTGS2 (0.39) | KIF11PTGS2AKR1C3AKR1C2 | |
| SCHEMBL10192373 | 0.75 | HRH4 (0.39) | PTGS2SMN1; SMN2 | |
| SCHEMBL22624027 | 0.74 | PDE2A (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18367838 | 0.73 | PDE2A (0.41) | PDE2A | |
| SCHEMBL18367835 | 0.73 | PDE2A (0.41) | PDE2A | |
| SCHEMBL16509490 | 0.72 | KIF11 (0.39) | KIF11PTGS2SMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL646030 | 0.72 | PTGS2 (0.56) | KIF11PTGS2 | |
| SCHEMBL30041432 | 0.72 | PTGS2 (0.56) | KIF11PTGS2 | |
| SCHEMBL18367829 | 0.72 | APLNR (0.46) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | KIF11 835/4885PTGS2 2694/4885SMN1; SMN2 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.